Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.34 |
| ▸ | CDK2 | P24941 | 3/20 | 0.34 |
| ▸ | CDK1 | P06493 | 2/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 4/20 | 0.34 |
| ▸ | JAK3 | P52333 | 4/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21588687 | 0.92 | FFAR1 (0.40) | FFAR1LRRK2IRAK4CCNE1CDK2 | |
| SCHEMBL18010602 | 0.92 | FFAR1 (0.43) | FFAR1LRRK2MPOIRAK4MKNK1 | |
| SCHEMBL1954029 | 0.92 | FFAR1 (0.43) | FFAR1LRRK2MPOIRAK4MKNK1 | |
| SCHEMBL17102316 | 0.92 | FFAR1 (0.43) | FFAR1LRRK2MPOIRAK4MKNK1 | |
| SCHEMBL1987497 | 0.91 | FFAR1 (0.49) | FFAR1LRRK2MPOIRAK4JAK1 | |
| SCHEMBL21588746 | 0.91 | FFAR1 (0.40) | FFAR1LRRK2MPOIRAK4CCNE1 | |
| SCHEMBL2572488 | 0.88 | FFAR1 (0.47) | FFAR1LRRK2MPOIRAK4JAK1 | |
| SCHEMBL2517121 | 0.88 | FFAR1 (0.47) | FFAR1MPOIRAK4JAK1JAK3 | |
| SCHEMBL2749177 | 0.87 | FFAR1 (0.46) | FFAR1MPOIRAK4CCNE1CDK2 | |
| SCHEMBL17801242 | 0.87 | FFAR1 (0.46) | FFAR1MPOIRAK4CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 529 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113248437-B | Tetraphenyl vinyl poly-pyrazole nitrogen-containing heterocyclic compound and preparation method and application thereof | 北京工业大学 | 2022-11-18 | — | — | CN | claimed |
| CN-113248437-A | Tetraphenyl vinyl poly-pyrazole nitrogen-containing heterocyclic compound and preparation method and application thereof | 北京工业大学 | 2021-08-13 | — | — | CN | claimed |
| CN-113201142-A | Hydrogen bond organic grid material based on aromatic tetrapyrazole and preparation method and application thereof | 北京工业大学 | 2021-08-03 | — | — | CN | claimed |
| CN-109456309-B | Multi-pyrazole nitrogen-containing heterocyclic compound and preparation and application thereof | 北京工业大学 | 2020-11-27 | — | — | CN | claimed |
| US-20260138986-A1 | PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | BLUEPRINT MEDICINES CORP (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026102563-A1 | DISUBSTITUTED PYRIMIDOPYRROLE ANALOG AND USE THEREOF | 深圳湾实验室坪山生物医药研发转化中心 | 2026-05-21 | — | — | WO | disclosed |
| EP-4724431-A1 | BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND USE THEREOF | Beone Medicines I GmbH (CH) | 2026-04-15 | — | — | EP | disclosed |
| US-20260098044-A1 | TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1 | INCYTE CORP (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260085053-A1 | BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2026-03-26 | — | — | US | disclosed |
| EP-4713095-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | Chengdu Anticancer Bioscience, Ltd. (CN) | 2026-03-25 | — | — | EP | disclosed |
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250353842-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORP (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2010048131-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010048131-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20100063031-A1 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063031-A1 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20090215776-A1 | Organic compounds | ADCOCK CLAIRE | 2009-08-27 | — | — | US | disclosed |
| WO-2009087212-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009024825-A1 | 2-PYRAZINYLBENZIMIDAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| WO-2008148867-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085053-A1 | BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF | SIK1, CHUK, SIK2 | FFAR1 1410/4885LRRK2 1045/4885MPO 1542/4885 |
| US-20090215776-A1 | Organic compounds | REN, RXFP1, MYLK | FFAR1 256/4885LRRK2 2666/4885MPO 319/4885 |
| US-20100063031-A1 | KINASE INHIBITOR COMPOUNDS | MAP4K2, MAP3K5, MAP3K15 | FFAR1 4647/4885LRRK2 445/4885MPO 4680/4885 |
| US-20250353842-A1 | BICYCLIC AMINE CDK12 INHIBITORS | CDK12, CDK1, CDK2 | FFAR1 4858/4885LRRK2 447/4885MPO 4315/4885 |
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | FFAR1 1016/4885LRRK2 779/4885MPO 4382/4885 |
| US-20260138986-A1 | PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | KIT, PDGFRA, PDGFRB | FFAR1 766/4885LRRK2 278/4885MPO 2312/4885 |
| US-20260098044-A1 | TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1 | JAK1, TYK2, JAK2 | FFAR1 452/4885LRRK2 261/4885MPO 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.